Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director · Chief Financial Officer | January 27, 2026 | January 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUCELL CORP /DE/
Report date January 27, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.27 · Expires 2036-01-27 | Direct | 120,000 |
Reported balance
After 2026-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 120,000 · Balance 120,000 F1: Option grant made to Mr. Fiori in connection with his employment as Chief Financial Officer. The option shall be treated as an incentive stock option to the maximum extent permitted by the International Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 40,000 options on the first, second and third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option grant made to Mr. Fiori in connection with his employment as Chief Financial Officer. The option shall be treated as an incentive stock option to the maximum extent permitted by the International Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 40,000 options on the first, second and third anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Jan 29, 2026 16:43 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantStock Options (right to buy) · Derivative | 120,000 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001437749-26-002371 · rdgdoc.xml · derivative · entry 1 Fiori Timothy C · CIK 0002063933 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-01-27 F1 · derivative.exercise_date: Option grant made to Mr. Fiori in connection with his employment as Chief Financial Officer. The option shall be treated as an incentive stock option to the maximum extent permitted by the International Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 40,000 options on the first, second and third anniversary of the grant date. Read SEC document |
| April 16, 2025 Filed Apr 23, 2025 16:53 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 30,000 | $5.49 Strike: $5.49 | $164,700.00 |
DisclosureSEC source: 0001213900-25-034500 · marketforms-69199.xml · derivative · entry 1 Fiori Timothy C · CIK 0002063933 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-04-16 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.